Short answer
ARVINAS, INC. (ARVN) filed an 8-K current report with the SEC on August 4, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Second-quarter 2026 financial results for period ended June 30, 2026.
ARVINAS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Second-quarter 2026 financial results for period ended June 30, 2026
- Corporate update announced alongside quarterly results
- Full results and operational details in Exhibit 99.1 пресс release
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $249.7M vs $22.4M, driven by $126.4M deferred-revenue recognition, $62.5M Rigel license revenue, and $50.0M approval milestone
- VEPPANU became the first FDA-approved PROTAC, while Rigel obtained exclusive global rights, shifting commercialization execution away from Arvinas
- Q2 net income $169.4M vs $61.2M loss, primarily reflecting collaboration and licensing revenue rather than recurring product sales
- Cash, equivalents and marketable securities $567.9M, sufficient under current plans into the second half of 2028
- Key catalysts: ARV-806 data in 2H 2026, ARV-6723 Phase 1 initiation in 3Q 2026, and ARV-393 data in 2H 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ARVINAS, INC. 8-K filings
Get the next ARVN 8-K as it lands
Follow ARVN for push alerts, or ask the research agent what this filing means.